Improving Patient Reported Outcome Measures in Catheter Ablation

Quality of Life Clinical Trial

Official title:

Use of Patient Reported Outcome Measures (PROMs) to Assess Quality of Life and Economic Evaluation of Cardiac Catheter Ablation of Ventricular Tachycardia: a Feasibility and Cohort Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04499326
• Other study ID #: IRAS 264743
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 1, 2023
• Est. completion date: October 1, 2024

Study information

• Verified date: August 2022
• Source: Barts & The London NHS Trust
• Contact: Yang Chen, BM BCh
• Phone: 02034165000
• Email: yang.chen[@]nhs.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess whether more frequent measurement of patient reported outcome measures (PROMs) - specifically health related quality of life (HRQL) - can improve the evaluation of the clinical effectiveness and cost-effectiveness of catheter ablation of ventricular tachycardia (VT) in patients with an Implantable Cardioverter Defibrillator (ICD). It is designed to have feasibility outcomes which contribute to answering the above.

Description:

Patients who have been implanted with an ICD are at risk of suffering from dangerous arrhythmias such as VT. Patients can experience clinical events including worsening of any underlying heart failure regardless of either VT ablation or medical therapy treatment strategy (anti-arrhythmic drugs (AAD)). VT ablation is a specialist procedure which has been proven in randomised clinical trials (RCTs) to confer symptomatic relief from VT, reduced hospitalisations and reduced shocks from ICDs. However, there is no effect on mortality. The frequent nature of clinical events in this group of patients may affect their health status quite dramatically and yet based on current trial evidence, only 3 out of 6 randomised trials in VT ablation reported PROMs. This can lead to brittle conclusions about the overall cost-effectiveness profile of a procedure such as VT ablation. This study will assess for the feasibility of more frequent HRQL monitoring and its impact on whether it is able to better capture the clinical narrative and quality of life changes of patients with severe heart failure and an ICD. And thus the assessment of both clinical effectiveness and cost effectiveness of catheter ablation of VT or continuing anti arrhythmic drug therapy. METHOD & SETTING Single centre study at St Bartholomew's Hospital London. Patients will be identified through established local pathways - there are traditional outpatient specialist clinics where Consultant Cardiologists receive referrals of patients for consideration of managing patients with VT, including ablation. In addition, there are joint VT clinics operated by Consultants as well as by cardiac physiologists. In the outpatient VT clinic, 85 patients were seen in a 10-month window - it is assumed that this scale will allow feasible identification of patients to be recruited to the both the groups of this study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: October 1, 2024
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Adults (>18 years) With an Implantable Cardioverter Defibrillator (ICD) implanted >3 months from time of recruitment and a previous episode of documented VT requiring therapy from the ICD. And impaired LV/RV function Willing and able to give written informed consent Exclusion Criteria: Patients who are planning to move away from study site within 12 months of enrolment who wished to use postal method to complete their HRQL Patients who are unable to give informed consent

Related Conditions & MeSH terms

• ICD
• Quality of Life
• Tachycardia
• Tachycardia, Ventricular
• Ventricular Tachycardia

Intervention

Other:
• Validated quality of life questionnaire (EQ-5D & C-CAP)
Patient quality of life to be assessed at baseline, 1, 2, 3, 4, 6, 9 and 12 months

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Barts & The London NHS Trust	University College, London

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Completion rate of HRQL forms for patients undergoing VT ablation and those starting or continuing AAD therapy		1 year follow up
Secondary	Recruitment rate of patients who fulfil study criteria		1 year
Secondary	- Patient preferences for either paper or electronic HQRL (as a percentage of total recruitment)		1 year
Secondary	Patient reported HRQL of VT ablation and AAD therapy on both EQ-5D and C-CAP		18 months
Secondary	Impact on the cost-effectiveness calculation of VT ablation (using EQ-5D, and a number of different EQ-5D data points)	Using the Incremental Cost-effectiveness ratio	18 months